NGN RN Pharmacology Proctored Exam Prep Document |
2026/2027 Edition | 250 Verified Questions
NGN RN Pharmacology Proctored Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest NGN Guidelines | Graded A+
This comprehensive test bank contains 250 verified questions and answers designed to prepare nursing
students for the NGN RN Pharmacology Proctored Exam. Each question reflects the latest NGN
guidelines and includes detailed rationales for correct and incorrect answers. The content covers key
pharmacology topics essential for safe and effective nursing practice. This resource is ideal for
self-assessment and mastery of pharmacological principles.
Key Features:
Pharmacokinetics and pharmacodynamics
Medication administration and safety
Drug classifications and interactions
Patient education and monitoring
Dosage calculations and IV therapy
Adverse effects and contraindications
Updates for 2026:
- Incorporated 2026 NGN test plan updates
- Added new questions on biologic and targeted therapies
- Revised rationales for clarity and accuracy
- Updated drug names to reflect latest formulary changes
- Enhanced dosage calculation scenarios with realistic clinical data
Abstract:
The NGN RN Pharmacology Proctored Exam is a critical assessment of a nursing student's ability to apply
pharmacological knowledge in clinical settings. This test bank comprises 250 meticulously curated questions that
mirror the format and difficulty of the actual exam. Each question is accompanied by a comprehensive rationale
explaining the correct answer and why the distractors are incorrect, promoting deeper understanding. Topics span
from basic pharmacokinetics to complex medication management across various patient populations. The
questions are designed to test not only recall but also clinical judgment and application. This resource is updated
to reflect the 2026/2027 NGN test plan, ensuring relevance and alignment with current nursing standards. By
engaging with these questions, students can identify knowledge gaps and build confidence for exam day. The
inclusion of dosage calculations and safety protocols reinforces essential competencies for nursing practice.
Keywords:
NGN RN Pharmacology, Proctored Exam, Test Bank, 250 Questions, Pharmacology Review, Nursing Exam Prep,
Medication Safety, Clinical Judgment
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining the underlying pharmacology
principle. Distractor answers are analyzed to clarify common misconceptions. This format supports active learning
and retention.
Compliance Checklist:
Aligned with 2026/2027 NGN test plan
All questions verified for accuracy
Rationales include evidence-based references
Page 1
, Covers all major pharmacology content areas
Suitable for self-study and group review
Includes dosage calculation practice
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion; receptor theory; dose-response
relationships
Medication Administration and 41-80 Routes of administration, rights of 16%
Safety medication administration, error prevention,
high-alert medications
Drug Classifications and 81-130 Antihypertensives, antibiotics, analgesics, 20%
Interactions psychotropics, drug-drug interactions
Patient Education and 131-170 Adverse effects, therapeutic monitoring, 16%
Monitoring patient teaching, cultural considerations
Dosage Calculations and IV 171-210 Dosage calculations, IV drip rates, titration, 16%
Therapy parenteral nutrition
Special Populations and 211-250 Pediatric, geriatric, pregnancy, renal/hepatic 16%
Advanced Topics impairment, oncology, biologic therapies
Page 2
,Q1. A patient with a history of chronic heart failure (NYHA class III) and atrial fibrillation is started on
digoxin. Which of the following concurrent medications most significantly increases the risk of digoxin
toxicity by reducing its renal clearance?
A. Amiodarone
B. Spironolactone
C. Metoprolol
D. Furosemide
Correct Answer: A. Amiodarone
Rationale: Amiodarone inhibits P-glycoprotein and reduces renal tubular secretion of digoxin, increasing serum
digoxin levels and toxicity risk. Spironolactone may cause hyperkalemia but does not alter digoxin clearance.
Metoprolol and furosemide do not significantly affect digoxin pharmacokinetics.
Why Wrong:
B - Spironolactone does not reduce digoxin clearance; it may increase potassium levels, but this does not
directly cause digoxin toxicity.
C - Metoprolol does not alter digoxin pharmacokinetics; it only masks signs of digoxin toxicity (e.g.,
tachycardia).
D - Furosemide may cause hypokalemia, which potentiates digoxin toxicity, but it does not reduce digoxin
clearance.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 44.
Q2. A patient receiving vancomycin for a methicillin-resistant Staphylococcus aureus (MRSA) infection
develops acute kidney injury. Which pharmacodynamic principle best explains the relationship between
vancomycin exposure and nephrotoxicity?
A. Area under the curve (AUC) to minimum inhibitory concentration (MIC) ratio
B. Peak concentration (Cmax) to MIC ratio
C. Trough concentration and duration of therapy
D. Time above MIC (T>MIC)
Correct Answer: C. Trough concentration and duration of therapy
Rationale: Vancomycin nephrotoxicity is most strongly associated with elevated trough concentrations (typically
>15-20 mcg/mL) and prolonged therapy duration, rather than AUC/MIC or peak concentration. AUC/MIC is a
predictor of efficacy, not toxicity. T>MIC is relevant for beta-lactams, not vancomycin.
Why Wrong:
A - AUC/MIC ratio is a marker of efficacy, not nephrotoxicity.
B - Peak concentration is not primarily linked to vancomycin nephrotoxicity.
D - T>MIC is a pharmacodynamic parameter for beta-lactam antibiotics, not vancomycin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 82.
Q3. A patient with type 2 diabetes mellitus and chronic kidney disease (eGFR 35 mL/min/1.73 m²) is
prescribed metformin. According to current FDA guidelines, which action is most appropriate?
A. Continue metformin at the same dose; no adjustment needed.
B. Discontinue metformin due to contraindication at this eGFR.
C. Reduce metformin dose by 50% and monitor renal function monthly.
D. Switch to a sulfonylurea to avoid any risk of lactic acidosis.
Correct Answer: B. Discontinue metformin due to contraindication at this eGFR.
Rationale: Current FDA guidelines contraindicate metformin use when eGFR falls below 30 mL/min/1.73 m², and
recommend reassessing benefits/risks when eGFR is 30-45 mL/min/1.73 m². At eGFR 35, the risk of lactic acidosis
outweighs benefit, so metformin should be discontinued. Dose reduction is not recommended; alternative therapy is
indicated.
Page 3
, Why Wrong:
A - Metformin is not safe at eGFR 35 without dose adjustment; however, current guidelines recommend discontinuation
at eGFR <30, and caution at 30-45.
C - Dose reduction is not a standard recommendation; discontinuation is preferred when eGFR is <30 or if renal function
is declining.
D - Switching to a sulfonylurea is an option, but the question asks about metformin management specifically.
Reference: FDA Drug Safety Communication (2016) and Lehne (2026), Ch. 68.
Q4. A patient on long-term warfarin therapy for mechanical heart valve is prescribed a course of fluconazole
for a fungal infection. Which mechanism best explains the increased international normalized ratio (INR)
observed after starting fluconazole?
A. Fluconazole displaces warfarin from plasma protein binding sites.
B. Fluconazole inhibits cytochrome P450 2C9, reducing warfarin metabolism.
C. Fluconazole induces warfarin metabolism, increasing clearance.
D. Fluconazole reduces vitamin K absorption from the gut.
Correct Answer: B. Fluconazole inhibits cytochrome P450 2C9, reducing warfarin metabolism.
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the primary enzyme responsible for metabolizing
S-warfarin. Inhibition decreases warfarin clearance, leading to elevated INR and increased bleeding risk.
Displacement from protein binding is transient and clinically insignificant. Induction would decrease INR, not
increase.
Why Wrong:
A - Protein binding displacement is a minor, transient effect; it does not explain sustained INR elevation.
C - Induction of warfarin metabolism would decrease INR, opposite of the observed effect.
D - Fluconazole does not affect vitamin K absorption.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34.
Q5. A patient with major depressive disorder is started on phenelzine, a monoamine oxidase inhibitor
(MAOI). Which dietary instruction is most critical to prevent a hypertensive crisis?
A. Avoid foods high in tyramine, such as aged cheeses and cured meats.
B. Limit caffeine intake to no more than two cups of coffee per day.
C. Increase fluid intake to prevent dehydration and orthostatic hypotension.
D. Take the medication with a high-protein meal to reduce gastrointestinal upset.
Correct Answer: A. Avoid foods high in tyramine, such as aged cheeses and cured meats.
Rationale: MAOIs irreversibly inhibit monoamine oxidase, preventing the breakdown of tyramine. Ingesting
tyramine-rich foods can cause a massive release of norepinephrine, leading to hypertensive crisis. Caffeine is not a
significant risk. High-protein meals do not affect MAOI safety.
Why Wrong:
B - Caffeine may cause mild cardiovascular effects but does not trigger hypertensive crisis with MAOIs.
C - Hydration is generally good but not specific to preventing hypertensive crisis.
D - Food interactions are not protein-related; tyramine content is the key concern.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29.
Q6. A patient with asthma is prescribed a long-acting beta-agonist (LABA) as add-on therapy to an inhaled
corticosteroid (ICS). Which statement best reflects the current safety concern regarding LABA
monotherapy?
A. LABA monotherapy is associated with increased risk of asthma-related death.
B. LABA monotherapy causes adrenal suppression more frequently than ICS.
C. LABA monotherapy is more effective than ICS alone for long-term control.
D. LABA monotherapy has a higher incidence of oropharyngeal candidiasis.
Page 4
2026/2027 Edition | 250 Verified Questions
NGN RN Pharmacology Proctored Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest NGN Guidelines | Graded A+
This comprehensive test bank contains 250 verified questions and answers designed to prepare nursing
students for the NGN RN Pharmacology Proctored Exam. Each question reflects the latest NGN
guidelines and includes detailed rationales for correct and incorrect answers. The content covers key
pharmacology topics essential for safe and effective nursing practice. This resource is ideal for
self-assessment and mastery of pharmacological principles.
Key Features:
Pharmacokinetics and pharmacodynamics
Medication administration and safety
Drug classifications and interactions
Patient education and monitoring
Dosage calculations and IV therapy
Adverse effects and contraindications
Updates for 2026:
- Incorporated 2026 NGN test plan updates
- Added new questions on biologic and targeted therapies
- Revised rationales for clarity and accuracy
- Updated drug names to reflect latest formulary changes
- Enhanced dosage calculation scenarios with realistic clinical data
Abstract:
The NGN RN Pharmacology Proctored Exam is a critical assessment of a nursing student's ability to apply
pharmacological knowledge in clinical settings. This test bank comprises 250 meticulously curated questions that
mirror the format and difficulty of the actual exam. Each question is accompanied by a comprehensive rationale
explaining the correct answer and why the distractors are incorrect, promoting deeper understanding. Topics span
from basic pharmacokinetics to complex medication management across various patient populations. The
questions are designed to test not only recall but also clinical judgment and application. This resource is updated
to reflect the 2026/2027 NGN test plan, ensuring relevance and alignment with current nursing standards. By
engaging with these questions, students can identify knowledge gaps and build confidence for exam day. The
inclusion of dosage calculations and safety protocols reinforces essential competencies for nursing practice.
Keywords:
NGN RN Pharmacology, Proctored Exam, Test Bank, 250 Questions, Pharmacology Review, Nursing Exam Prep,
Medication Safety, Clinical Judgment
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining the underlying pharmacology
principle. Distractor answers are analyzed to clarify common misconceptions. This format supports active learning
and retention.
Compliance Checklist:
Aligned with 2026/2027 NGN test plan
All questions verified for accuracy
Rationales include evidence-based references
Page 1
, Covers all major pharmacology content areas
Suitable for self-study and group review
Includes dosage calculation practice
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion; receptor theory; dose-response
relationships
Medication Administration and 41-80 Routes of administration, rights of 16%
Safety medication administration, error prevention,
high-alert medications
Drug Classifications and 81-130 Antihypertensives, antibiotics, analgesics, 20%
Interactions psychotropics, drug-drug interactions
Patient Education and 131-170 Adverse effects, therapeutic monitoring, 16%
Monitoring patient teaching, cultural considerations
Dosage Calculations and IV 171-210 Dosage calculations, IV drip rates, titration, 16%
Therapy parenteral nutrition
Special Populations and 211-250 Pediatric, geriatric, pregnancy, renal/hepatic 16%
Advanced Topics impairment, oncology, biologic therapies
Page 2
,Q1. A patient with a history of chronic heart failure (NYHA class III) and atrial fibrillation is started on
digoxin. Which of the following concurrent medications most significantly increases the risk of digoxin
toxicity by reducing its renal clearance?
A. Amiodarone
B. Spironolactone
C. Metoprolol
D. Furosemide
Correct Answer: A. Amiodarone
Rationale: Amiodarone inhibits P-glycoprotein and reduces renal tubular secretion of digoxin, increasing serum
digoxin levels and toxicity risk. Spironolactone may cause hyperkalemia but does not alter digoxin clearance.
Metoprolol and furosemide do not significantly affect digoxin pharmacokinetics.
Why Wrong:
B - Spironolactone does not reduce digoxin clearance; it may increase potassium levels, but this does not
directly cause digoxin toxicity.
C - Metoprolol does not alter digoxin pharmacokinetics; it only masks signs of digoxin toxicity (e.g.,
tachycardia).
D - Furosemide may cause hypokalemia, which potentiates digoxin toxicity, but it does not reduce digoxin
clearance.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 44.
Q2. A patient receiving vancomycin for a methicillin-resistant Staphylococcus aureus (MRSA) infection
develops acute kidney injury. Which pharmacodynamic principle best explains the relationship between
vancomycin exposure and nephrotoxicity?
A. Area under the curve (AUC) to minimum inhibitory concentration (MIC) ratio
B. Peak concentration (Cmax) to MIC ratio
C. Trough concentration and duration of therapy
D. Time above MIC (T>MIC)
Correct Answer: C. Trough concentration and duration of therapy
Rationale: Vancomycin nephrotoxicity is most strongly associated with elevated trough concentrations (typically
>15-20 mcg/mL) and prolonged therapy duration, rather than AUC/MIC or peak concentration. AUC/MIC is a
predictor of efficacy, not toxicity. T>MIC is relevant for beta-lactams, not vancomycin.
Why Wrong:
A - AUC/MIC ratio is a marker of efficacy, not nephrotoxicity.
B - Peak concentration is not primarily linked to vancomycin nephrotoxicity.
D - T>MIC is a pharmacodynamic parameter for beta-lactam antibiotics, not vancomycin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 82.
Q3. A patient with type 2 diabetes mellitus and chronic kidney disease (eGFR 35 mL/min/1.73 m²) is
prescribed metformin. According to current FDA guidelines, which action is most appropriate?
A. Continue metformin at the same dose; no adjustment needed.
B. Discontinue metformin due to contraindication at this eGFR.
C. Reduce metformin dose by 50% and monitor renal function monthly.
D. Switch to a sulfonylurea to avoid any risk of lactic acidosis.
Correct Answer: B. Discontinue metformin due to contraindication at this eGFR.
Rationale: Current FDA guidelines contraindicate metformin use when eGFR falls below 30 mL/min/1.73 m², and
recommend reassessing benefits/risks when eGFR is 30-45 mL/min/1.73 m². At eGFR 35, the risk of lactic acidosis
outweighs benefit, so metformin should be discontinued. Dose reduction is not recommended; alternative therapy is
indicated.
Page 3
, Why Wrong:
A - Metformin is not safe at eGFR 35 without dose adjustment; however, current guidelines recommend discontinuation
at eGFR <30, and caution at 30-45.
C - Dose reduction is not a standard recommendation; discontinuation is preferred when eGFR is <30 or if renal function
is declining.
D - Switching to a sulfonylurea is an option, but the question asks about metformin management specifically.
Reference: FDA Drug Safety Communication (2016) and Lehne (2026), Ch. 68.
Q4. A patient on long-term warfarin therapy for mechanical heart valve is prescribed a course of fluconazole
for a fungal infection. Which mechanism best explains the increased international normalized ratio (INR)
observed after starting fluconazole?
A. Fluconazole displaces warfarin from plasma protein binding sites.
B. Fluconazole inhibits cytochrome P450 2C9, reducing warfarin metabolism.
C. Fluconazole induces warfarin metabolism, increasing clearance.
D. Fluconazole reduces vitamin K absorption from the gut.
Correct Answer: B. Fluconazole inhibits cytochrome P450 2C9, reducing warfarin metabolism.
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the primary enzyme responsible for metabolizing
S-warfarin. Inhibition decreases warfarin clearance, leading to elevated INR and increased bleeding risk.
Displacement from protein binding is transient and clinically insignificant. Induction would decrease INR, not
increase.
Why Wrong:
A - Protein binding displacement is a minor, transient effect; it does not explain sustained INR elevation.
C - Induction of warfarin metabolism would decrease INR, opposite of the observed effect.
D - Fluconazole does not affect vitamin K absorption.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34.
Q5. A patient with major depressive disorder is started on phenelzine, a monoamine oxidase inhibitor
(MAOI). Which dietary instruction is most critical to prevent a hypertensive crisis?
A. Avoid foods high in tyramine, such as aged cheeses and cured meats.
B. Limit caffeine intake to no more than two cups of coffee per day.
C. Increase fluid intake to prevent dehydration and orthostatic hypotension.
D. Take the medication with a high-protein meal to reduce gastrointestinal upset.
Correct Answer: A. Avoid foods high in tyramine, such as aged cheeses and cured meats.
Rationale: MAOIs irreversibly inhibit monoamine oxidase, preventing the breakdown of tyramine. Ingesting
tyramine-rich foods can cause a massive release of norepinephrine, leading to hypertensive crisis. Caffeine is not a
significant risk. High-protein meals do not affect MAOI safety.
Why Wrong:
B - Caffeine may cause mild cardiovascular effects but does not trigger hypertensive crisis with MAOIs.
C - Hydration is generally good but not specific to preventing hypertensive crisis.
D - Food interactions are not protein-related; tyramine content is the key concern.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29.
Q6. A patient with asthma is prescribed a long-acting beta-agonist (LABA) as add-on therapy to an inhaled
corticosteroid (ICS). Which statement best reflects the current safety concern regarding LABA
monotherapy?
A. LABA monotherapy is associated with increased risk of asthma-related death.
B. LABA monotherapy causes adrenal suppression more frequently than ICS.
C. LABA monotherapy is more effective than ICS alone for long-term control.
D. LABA monotherapy has a higher incidence of oropharyngeal candidiasis.
Page 4
